Results 61 to 70 of about 399,504 (355)

Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.

open access: yesOncology Letters, 2017
As a derivative of artemisinin, dihydroartemisinin is effective in the treatment of malaria. Dihydroartemisinin has been identified to possess inhibitory effects in numerous types of animal model with tumors, indicating that it has an antineoplastic ...
Dongsheng Wang   +3 more
semanticscholar   +1 more source

c-Abl Activates Janus Kinase 2 in Normal Hematopoietic Cells [PDF]

open access: yesJournal of Biological Chemistry, 2014
Jak2 is involved in cytokine growth factor-stimulated signal transduction, but the mechanism of its activation is largely unknown. Here, we investigated Jak2 activation in a normal hematopoietic cell line, 32D mouse myeloid cells. The bimolecular fluorescence complementation studies showed that c-Abl formed a stable complex with Jak2 in live cells.
Wenjing, Tao   +4 more
openaire   +2 more sources

Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway

open access: yesTumor Biology, 2017
Long non-coding RNA HOXD-AS1 (HOXD cluster antisense RNA 1) has been demonstrated to be closely associated with the progression of several tumors. However, the biological function of HOXD-AS1 and the underlying molecular mechanism in gastric cancer are ...
Li Zheng   +3 more
doaj   +1 more source

Suggested modification of Janus associated kinase 2-tree algorithm for the detection of Janus associated kinase 2 V617F-positive polycythemia rubra vera patients in Pakistani population

open access: yesJournal of Applied Hematology, 2020
OBJECTIVE: The Janus associated kinase-2 (JAK2 mutation V617F and exon 12) is detected in most polycythemia vera (PV) patients. It can easily be picked up by real-time polymerase chain reaction (PCR).
Mohammad Abdul Naeem, Mohammad Iqbal
doaj   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

open access: yesPostgraduate Medicine, 2013
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
openaire   +2 more sources

Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+-dependent calcineurin signaling

open access: yesJournal of Lipid Research, 2010
ATP-binding cassette transporter A1 (ABCA1) is required for the lipidation of apolipoprotein A-I (apoA-I), although molecular mechanisms supporting this process remain poorly defined.
Joel Karwatsky   +3 more
doaj   +1 more source

Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. [PDF]

open access: yesPLoS Computational Biology, 2013
The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis.
Xiaobo Wan   +4 more
doaj   +1 more source

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults

open access: yesКачественная клиническая практика, 2022
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin   +3 more
doaj   +1 more source

Dietary Polyphenols and Periodontitis—A Mini-Review of Literature [PDF]

open access: yes, 2018
Periodontitis, which is a chronic infection and disease of the periodontium, is a significant global health burden and is linked to other chronic health conditions such as diabetes and cardiovascular diseases.
Basu, Arpita   +2 more
core   +2 more sources

Successful treatment of pyoderma gangrenosum with Janus kinase 1/2 inhibition

open access: yesJEADV Clinical Practice, 2022
Pyoderma gangrenosum (PG) is a rare, autoinflammatory disease leading to painful, hard‐to‐treat ulcers. Besides systemic glucocorticoids, a plethora of classic immunosuppressants, biologics and small molecules have been reported to improve PG disease ...
Sebastian Sitaru   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy